Search

Displaying results 1971 - 1980 of 10000 in total
  1. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development. … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

  2. Drug

    Robalzotan

    go.drugbank.com/drugs/DB06538
    Experimental

    Synonyms: (R)-3-(Dicyclobutylamino)-8-fluoro-5-chromancarboxamideCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  3. Drug

    R107474

    go.drugbank.com/drugs/DB06553
    Experimental

    Synonyms: 3-(2-(3,4-Dihydrobenzofuro(3,2-c)pyridin-2(1H)-yl)ethyl)-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one, 3-[2-(3,4-dihydro-1H-[1]benzofuro[3,2-c]pyridin-2-yl)ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-oneCategories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Siramesine

    go.drugbank.com/drugs/DB06555
    Experimental

    Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Tezosentan

    go.drugbank.com/drugs/DB06558
    Investigational

    Tezosentan is an intravenous endothelin receptor A/B antagonist.

    Categories: Heterocyclic Compounds, 1-Ring
  6. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    It was investigated as a potential treatment for various pain conditions. … Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

    Categories: Calcium Channels, N-Type
  7. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression

    Categories: Histocompatibility Antigens Class I
  8. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid

  9. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  10. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MG